Cardiac Toxicity in Medical Treatment of Breast Cancer
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 45
- 试验地点
- 1
- 主要终点
- Global longitudinal strain by two dimentional speckle tracking.
研究概览
简要总结
This study will describe the epidemiology including prognosis of heart failure related to treatment with anthracycline and trastuzumab for breast cancer.
In a prospective study Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer patients scheduled for trastuzumab treatment at Odense University Hospital, will be offered advanced echocardiographic examination, test of bio-markers and genetic markers for the purpose of investigating if early identification of patients in particular risk of developing heart failure is feasible.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of HER2 positive breast cancer
- •Adjuvant treatment with trastuzumab
排除标准
- •Left ventricle ejection fraction (LVEF) <50%
- •Chronic or persistent atrial fibrillation
- •History of moderate or severe valvular heart disease.
结局指标
主要结局
Global longitudinal strain by two dimentional speckle tracking.
时间窗: Change in outcome from initiation of trastuzumab treatment and after 3,6, and 9 month.
Ratio between the mitral E velocity and early diastolic maximum global strain rate (E/SRE).
时间窗: Change in outcome from initiation of trastuzumab treatment and after 3,6, and 9 month.
次要结局
未报告次要终点
研究者
Ann Banke
MD, Ph.d.-student
Odense University Hospital